Brown Advisory, an investment management company, released its “Brown Advisory Mid-Cap Growth Strategy” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. The Strategy lagged the Russell Midcap® Growth Index in the fourth quarter due to stock selection. While the performance was in line with the expectations for the full year. The firm believes that the Strategy underperformed in 2025 because it did not own Palantir Technologies Inc (PLTR). The Strategy focuses on achieving so ...

Artisan Partners, an investment management company, released its fourth-quarter 2025 investor letter for “Artisan Small Cap Fund”. A copy of the letter can be downloaded here. The Fund seeks to invest in companies that possess franchise characteristics, with strong earnings trajectories, and are trading at a discount to the estimated private market value. Despite strong results in 2025, volatility was elevated, and sentiment shifted frequently, influenced by political developments in the US, evolving trade ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT of 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to __________ Commission File Number 000-30833 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 04-3110160 (Stat ...

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard. Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences. At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000 ...

Core Insights - Bruker's international revenue performance is crucial for assessing its financial resilience and growth prospects, especially given its global presence [1][2][3] Revenue Performance - The total revenue for Bruker in the last quarter was $977.2 million, reflecting a slight decline of 0.2% year over year [4] - Asia Pacific generated $301.2 million, accounting for 30.8% of total revenue, which was a surprise increase of +12.62% compared to the projected $267.46 million [5] - Other International contributed $74 million, making up 7.6% of total revenue, exceeding the consensus estimate of $58.31 million by +26.91% [6] Future Projections - Analysts project Bruker will report revenues of $798.04 million for the ongoing fiscal quarter, a decline of 0.4% from the previous year, with expected contributions from Asia Pacific and Other International at $251.4 million and $62.78 million, respectively [7] - For the full year, total revenue is expected to reach $3.59 billion, an increase of 4.5% from the previous year, with Asia Pacific and Other International projected to contribute $1.06 billion and $251.05 million, respectively [8] Market Dependency - Bruker's reliance on global markets for revenue presents both opportunities and challenges, making the monitoring of international revenue trends essential for predicting future performance [9][10] Stock Performance - Over the past month, Bruker's stock has declined by 23.5%, while the Zacks S&P 500 composite decreased by 1.3% [13] - In the last three months, the company's stock price has fallen by 22.7%, contrasting with a 2.9% rise in the S&P 500 index [13]

Core Insights - Bruker Corporation (BRKR) reported adjusted earnings per share (EPS) of 59 cents for Q4 2025, a decline of 22.4% year over year, and missed the Zacks Consensus Estimate by 9.2% [1][7] - The company’s total revenues for Q4 were $977.2 million, a slight decrease of 0.2% year over year, but exceeded the Zacks Consensus Estimate by 1.12% [3][10] - For the full year 2025, adjusted EPS was $1.83, down 24.1% from the previous year [2] Revenue Analysis - Q4 revenues by geography showed a 13.8% decline in the U.S. to $225 million, while Europe saw a 1% increase to $377 million, and Asia Pacific revenues rose 8.3% to $301.2 million [4] - The BSI BioSpin segment revenues fell 2% to $267 million, while BSI CALID revenues increased by 3.4% to $331.6 million [4] - Total revenues for 2025 reached $3.44 billion, reflecting a 2.1% increase from the previous year [3] Margin Performance - Gross profit decreased by 8.9% to $449.2 million, with gross margin contracting by 439 basis points to 46% due to an 8.6% rise in the cost of revenues [5][10] - Adjusted operating profit was $102.4 million, down 27.7% year over year, with adjusted operating margin contracting by 398 basis points to 10.5% [5] Financial Position - At the end of Q4 2025, Bruker had cash and cash equivalents of $298.8 million, an increase from $183.4 million at the end of 2024 [6] - Long-term debt at the end of Q4 2025 was $1.87 billion, down from $2.09 billion at the end of Q4 2024 [8] 2026 Guidance - Bruker provided guidance for 2026, expecting revenues between $3.57 billion and $3.60 billion, indicating a year-over-year growth of 4% to 5% [9] - Adjusted EPS for 2026 is projected to be in the range of $2.10 to $2.15, representing an increase of 15% to 17% year over year [9] Overall Assessment - The company ended Q4 2025 with mixed results, as earnings missed estimates while revenues surpassed them [10] - Margins were negatively impacted by lower volume, unfavorable mix, tariffs, and currency headwinds [10] - Despite challenges, Bruker’s innovation efforts showed promise, with expectations for improved contributions from the BEST segment in 2026 [11]

Core Viewpoint - Bruker Corp reported mixed financial results for the fourth quarter, with earnings per share falling short of analyst expectations while sales exceeded them [1] Financial Performance - Quarterly earnings were reported at 59 cents per share, missing the analyst consensus estimate of 65 cents per share [1] - Quarterly sales reached $977.200 million, surpassing the analyst consensus estimate of $960.834 million [1] Future Guidance - For FY2026, Bruker expects adjusted EPS to be in the range of $2.10 to $2.15, compared to market estimates of $2.13 [1] - The company anticipates sales between $3.570 billion and $3.600 billion, exceeding estimates of $3.470 billion [1] Stock Performance - Following the earnings announcement, Bruker shares increased by 1.6%, trading at $43.27 [2] Analyst Ratings and Price Targets - Barclays analyst Luke Sergott maintained an Overweight rating on Bruker but lowered the price target from $55 to $50 [3] - TD Cowen analyst Dan Brennan maintained a Hold rating and reduced the price target from $53 to $43 [3]

Bruker Corp (NASDAQ:BRKR) reported mixed fourth-quarter financial results on Thursday.Bruker reported quarterly earnings of 59 cents per share which missed the analyst consensus estimate of 65 cents per share. The company reported quarterly sales of $977.200 million which beat the analyst consensus estimate of $960.834 million.Bruker said it sees FY2026 adjusted EPS of $2.10-$2.15, versus market estimates of $2.13. The company sees sales of $3.570 billion-$3.600 billion versus estimates of $3.470 billion.Br ...

Core Viewpoint - Bruker Corporation is facing challenges in maintaining profit margins despite exceeding revenue estimates, leading to a cautious outlook from analysts [5][6]. Financial Performance - Bruker reported Q4 2025 revenue of $977.2 million, a slight decline of 0.2% year-over-year, but above the Zacks Consensus Estimate of $966.4 million, resulting in a positive surprise of 1.12% [2][6]. - The company's EPS for Q4 2025 was $0.59, which fell short of the consensus estimate of $0.65, representing a negative surprise of 9.23% and a decline from the previous year's EPS of $0.76 [3][6]. Stock Performance - The current stock price of $37.51 reflects an approximate decrease of 11.60% from previous levels, with a market capitalization of about $5.7 billion [4]. - Over the past year, BRKR's stock has fluctuated significantly, reaching a high of $56.22 and a low of $28.53 [4]. Analyst Outlook - Jefferies has lowered the price target for BRKR from $55 to $50, influenced by the recent earnings performance and the decline in EPS, despite the company's ability to exceed revenue estimates [5][6].

Non-GAAP diluted EPS was $0.59, down from $0.76 in the year-ago quarter. On a GAAP basis, diluted EPS was $0.10 versus $0.09. Herman also noted the weighted average diluted share count rose 13% year-over-year to 171.7 million shares, reflecting accounting for the mandatory convertible preferred stock offering completed in September 2025.Non-GAAP operating margin was 15.7%, down 240 basis points year-over-year. CFO Gerald Herman said the margin came in about 100 basis points below the company’s expectations, ...